Merck Scores FDA Approval for Welireg Plus Lenvima in Advanced Kidney Cancer

Merck (NYSE:MRK) and Eisai have received FDA approval for their combination treatment, Welireg plus Lenvima, in previously treated advanced clear cell renal cell carcinoma. The new regimen is cleared for adults whose kidney cancer progressed after prior PD-1 or PD-L1 inhibitor therapy.

The approval is backed by Phase 3 trial data that regulators used to support the use of the combination in the post-immunotherapy setting. Welireg plus Lenvima opens a fresh chapter for Merck in advanced kidney cancer, expanding its oncology footprint alongside broader work across treatments, vaccines, and other healthcare products worldwide.

Merck's market value is around $367.1 billion, making it a GB-based pharmaceuticals group with significant operations. The company is using this kidney cancer decision to position itself in a later line setting where many patients have already seen Keytruda, expanding the oncology footprint into a niche that previously leaned more heavily on drugs like cabozantinib.

The key test for Merck investors will be how quickly Welireg plus Lenvima gains share versus cabozantinib in previously treated advanced ccRCC. Prescription trends over the first full year after launch, especially the proportion of post PD-1 or PD-L1 patients moving to this oral combo, will show whether the regimen is translating trial data into real use.